Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CPI-006 + CPI-444|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CPI-006||CPI 006|CPI006|CPX-006||Adenosine Targeting 16 CD73 Antibody 7||CPI-006 is a monoclonal antibody against NT5E (CD73) that inhibits the conversion of AMP to adenosine to inhibit tumor growth and also has immunomodulatory activities (Journal of Clinical Oncology 2019 37:15_suppl, TPS2646).|
|CPI-444||Ciforadenant|V81444|CPI 444|CPI444||Adenosine Targeting 16||Ciforadenant (CPI-444) binds to and inhibits A2A (ADORA2A) on immune cells, which may increase anti-tumor immune response and inhibit tumor growth by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29923026, PMID: 30131376).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03454451||Phase I||CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444||CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers||Recruiting||USA||1|